2009 There are 1800 foreign funded pharmaceutical enterprises
The top 20 pharmaceutical
companies set up joint ventures in China.
This suggests that market
conditions have never been more challenging, with
competition at an
Pfizer produces and markets more than 40 drugs
in China all of which meet chinese pharmacopeia quality control.
Pfizer has manufacturing
facilities in Dalian, Suzhou and Wuxi.
The Pfizer Dalian
facility, built in 1989 jointly with Dalian Pharmaceuticals was the
first to get certification in China.
GlaxoSmithKline has more than 2000
employees in China, and its drugs are sold in 60 cities.
sells drugs treating HIV, asthma and infection.
Merck sells antibiotics
prostate drugs, cardiovascular drugs,
pain relievers, osteoporosis
and vaccines. Merck set up its first
joint venture in China in 1994.
Novartis has four
manufacturing facilities in Beijing and Shanghai.
Novartis core businesses
involve patented drugs,
generic drugs, eye protection drugs and
Novartis Beijing was founded by Novartis
AG and Beijing Pharmaceutical group and Beijing Zizhu
Pharmaceuticals in 1987 and was the first foreign pharmaceutical company in
German-French company, sells several drugs in China.
AstraZeneca has headquarters in
Shanghai, with 25 branch offices in major cities.
AstraZeneca established its largest manufacturing site in Asia in Wuxi.
several products, including the
antiPsychotic used in the management of
Seroquel(quetiapine) and Nexium(esomeprazole).
AstraZeneca has nearly 3,000 employees working in manufacturing,
research and new product development.
AstraZeneca has a
presence in more than 110 targeted cities, with around
Bristol-Myers Squibb was one of the
earliest to enter Chinese market.
Johnson & Johnson has established
subsidiaries which include Shanghai Johnson & Johnson Pharmaceuticals,
Ltd, Johnson & Johnson Medical (Shanghai) Ltd, Johnson &
Johnson Medical (China) Ltd, Johnson & Johnson (China) Ltd,
Johnson & Johnson (China) Investment Co., Ltd, manufacturing and
selling drugs in China.
Wyeth best-seller in China includes
Roche launched a medical education campaign
targeting 3,500 doctors in 20 Chinese cities in 2004.
Schering-Plough is the recognized
leader in biotech, genomics and gene therapy.
Schering-Plough Pharmaceutical Co., Ltd was founded in 1994 as a
joint-venture, with Shanghai Pharmaceutical Industry (Group) Corporation
and Shanghai Corporation of Pharmaceutical Economic and Technical
Bayer invests in the early 1990s in large-scale,
world-class facilities in an integrated production site in the Shanghai
Chemical Industry Park.
Operations, in Hong Kong, Taiwan, and China
are led by management holding companies, with subgroups and production joint
ventures operating independently under the strategic direction of Bayer.
Bayer has production facilities
on stream in all corporately active business lines. Chinese production accounts
for an increasing proportion of profit margins.
Bayer is engaged in a
number of coöperation projects with some of the foremost research
institutes and universities in China, to conduct research in the field of
innovative materials, health care and crop science.
coöperates with the Chinese Academy of Science and affiliated
institutes such as the Institute of Materia Medica and the Kunming
Institute of Botany in Yunnan with the aim to identify new compounds in the
healthcare and crop science field.
supports a number of chairs and programs for research and teaching at Chinese
These include the Tsinghua-Bayer Public Health and
HIV/AIDS Media Studies Program, a national platform designed to play a
key role in China's public health system.
supports a chair for Healthcare Management at the China European
International Business School (CEIBS) in Shanghai.
Ingelheim entered Chinese market in 1995 and invested $25 million in a new
facility in Shanghai in 2002.
Its drugs treating
diseases are established in Chinese pharmaceutical markets.
Hoechst Marion russell established its China head offices in
Beijing in 1995 to manage operations in mainland China and Hong Kong.
Hoechst Marion russell has two joint ventures in China,
Hoechst Huabei Pharmaceuticals Ltd in Shijiazhuang, a heartland of the
Chinese pharmaceutical industry, and Hoechst Shanghai International
Eli Lilly set up
its first overseas office in Shanghai in 1918 and returned to Shanghai, China
Eli Lilly main
facility is in Suzhou, Jiangsu province and main products include cipro,
insulin, and erectile
Abbott Laboratories Ltd sells a series of
products including baby food in China.
foreign-invested ventures in China, Xian-Janssen Pharmaceutical's
success is due to its product line, which includes a range of high-volume
sellers: medicines to treat gastronintestinal problems, fungi, allergies and
pain, as well as psychosis
Janssen's decision to enter China
early, to invest inland, and to keep investment plans moving along in the wake
of 1989 Tiananmen Square event have helped build good relations with the
Chinese government. Paul Appermont and Joos Horsten lead the Xian-Janssen
Degussa is shifting a large
proportion of its pharmaceutical chemicals production from Europe to China in
order to take advantage of low-cost manufacturing. Degussa will
restructure its large
production facilities, the vast majority in Germany, which could result in
the transfer of the manufacture of other products to China.
Rhodia is improving its competitive position in analgesics by
making a major investment in its Wuxi, China acetaminophen (paracetamol)
production facility and consolidating its North American and European
operations. Rhodia shuttered its Luling, Louisiana, acetaminophen
(paracetamol) operations in 2004 and consolidated production in Roussillon,
France and Wuxi, China. Acetaminophen (paracetamol) production capacity will be
adjusted to match current consumption levels.
Acetaminophen linked to autism?
Acetaminophen Linked to Lower Empathy Levels
Acetaminophen use in pregnancy linked to kids' behavioral
Mechanisms of Acetaminophen-Induced Liver Necrosis
11 Million Bottles Possibly Tainted With Metal
Sankyo has operated a plant for manufacturing the
hyperlipemic Mevalotin(pravastatin), anti-inflammatory
Loxonin(loxoprofen), antibiotic Banan(cephalosporin antibiotic)
and has plans to market hypertensive Olmesartan(angiotensin II receptor
Takeda has a manufacturing plant and will be
marketing all four global products - the thiazolidinedione with hypoglycemic
action Actos(pioglitazone), anti-ulcer proton pump
inhibitorTakepron(lansoprazole), gonadotropin-releasing hormone agonist
cancer drug Leuplin(leuprolide acetate), and hypertensive
Yamanouchi owns a manufacturing
plant and is marketing anti-ulcer histamine H2-receptor antagonist
Gaster(famotidine), urinary impediment treatment
Harnal(tamsulosin), a selective alpha blocker used in the symptomatic
treatment of benign prostatic hyperplasia and hypertensive calcium channel
blocker Hypoca. There are plans to launch Dolner for peripheral
circulation and anti-emetic Nazea OD.
sells synthetic antibacterials Cravit (oral and injectable levofloxacin)
and Tarivid(ofloxacin). It originally planned to launch
neurotransmission enhancer Translon too, but after development was
halted in Japan, development in China also ended. Sales are behind plan chiefly
due to the suspension of Translon's development and the proliferation of
generic and copycat versions of
Tanabe markets hypertensive
Herbesser(diltiazem hydrochloride) and Tanatril (imidapril
The China subsidiary Kuangchou Green Cross of
Mitsubishi Pharma has been extending transfusion business
(manufacturing, sales) since the days of the former Green Cross.
Mitsubishi Pharma sold its transfusion business in Japan to Otsuka
Pharmaceutical as part of a restructuring. Anti-coagulant
Novastan(argatroban) was launched in China in December 2002 and is being
sold by a local agent.
Immunosuppressant Prograf(tacrolimus or
fujimycin) is being marketed in China by a Fujisawa subsidiary -
potential is significant due to the ever increasing number of organ
transplants. In 2000, there were 5,501 kidney transplants performed in China,
second only to the number in the US (13,372). Sales of immunosuppressant drugs
are relatively high. The top 30 drugs by sales in China (hospital market base)
included two such drugs: Novartis' immunosuppressant drug used in
post-allogeneic organ transplantNeoral(cyclosporine) and Roche's
immunosuppressant drug used to prevent rejection in organ transplantation
CellCept (mycophenolate mofetil).
Chugai exports white
blood cell production stimulant Neutrogin (lenograstim) to China.
Kirin's granulocyte colony-stimulating factor is marketed in
Eisai expanded its manufacturing and marketing operations
in China and Asia earlier than in the European and US markets. Eisai was
the first manufacturer among the US, European and Japanese pharmaceutical firms
to manufacture in China via a 100% owned subsidiary which founded in 1994.
Eisai sells two global products, anti-ulcer proton pump inhibitors
Pariet(rabeprazole) and Alzheimer's acetylcholinesterase inhibitor
treatment Aricept(donepezil), and plans to add
Glakay(menatetrenone) in 2006.
Kyowa Hakko has exported
cancer drugs and plans to market the hypertensive dihydropyridine calcium
channel blockerConiel(benidipine) and anti-allergy antihistamine and
mast cell stabilizer Allelock(olopatadine
Taisho makes and sells health drinks (tonics) in
China, but has no specific plans for prescription medications. The rights to
macrolide antibiotic Clarith/Biaxin(clarithromycin) outside Japan
are licensed to Abbott.
Terumo is using China as a
manufacturing base making products for the US and European and Japanese
markets. Terumo is in the process of exploring China as a
The first foreign office of the
FDA opened November 19,
2008 in Beijing.
2009 McNeil Consumer Healthcare, a division of
Johnson & Johnson, announced
the recall of several hundred batches of popular over-the-counter medicines,
including Benadryl, Motrin, Rolaids, Simply Sleep, St. Joseph Aspirin and
The response was anything but swift.
The recall came 20
months after McNeil first began receiving consumer complaints about
moldy-smelling bottles of Tylenol Arthritis Relief caplets.
& Johnson did not conduct a timely, comprehensive investigation, did not
quickly identify the source of the problem, and did not notify authorities in a
timely fashion thus prolonging consumer exposure to the products.
This web site is not a commercial web site and
is presented for educational
This website defines a
new perspective with which to engage reality to which its author adheres. The
author feels that the falsification of reality outside personal experience has
forged a populace unable to discern propaganda
from reality and that this has been done purposefully by an international
corporate cartel through their agents who wish to foist a corrupt version of
reality on the human race. Religious intolerance occurs
when any group refuses to tolerate religious practices, religious beliefs or
persons due to their religious ideology. This web site marks the founding of a
system of philosophy named The Truth of the Way of the Lumière Infinie -
a rational gnostic mystery religion based on reason which requires no leap of
faith, accepts no tithes, has no supreme leader, no church buildings and in
which each and every individual is encouraged to develop a personal relation
with the Creator and Sustainer through the pursuit of the knowledge of reality
in the hope of curing the spiritual corruption that has enveloped the human
spirit. The tenets of The Truth of the Way of the Lumière Infinie are
spelled out in detail on this web site by the author. Violent acts against
individuals due to their religious beliefs in America is considered a "hate
This web site in no way condones violence. To the contrary the
intent here is to reduce the violence that is already occurring due to the
international corporate cartels desire to control the human race. The
international corporate cartel already
controls the world economic system, corporate media worldwide, the global
industrial military entertainment complex and is responsible for the collapse
of morals, the elevation of self-centered behavior and the destruction of
global ecosystems. Civilization is based on coöperation. Coöperation
does not occur at the point of a gun.
American social mores and values
have declined precipitously over the last century as the corrupt international
cartel has garnered more and more power. This power rests in the ability to
deceive the populace in general through corporate media by pressing emotional
buttons which have been preprogrammed into the population through prior mass
media psychological operations. The results have been the destruction of the
family and the destruction of social structures that do not adhere to the
corrupt international elites vision of a
perfect world. Through distraction and coercion the direction of thought of
the bulk of the population has been directed toward solutions proposed by the
corrupt international elite that further consolidates their power and which
further their purposes.
All views and opinions presented on this web
site are the views and opinions of individual human men and women that, through
their writings, showed the capacity for intelligent, reasonable, rational,
insightful and unpopular thought. All factual information presented on this web
site is believed to be true and accurate and is presented as originally
presented in print media which may or may not have originally presented the
facts truthfully. Opinion and thoughts have been adapted, edited, corrected,
redacted, combined, added to, re-edited and re-corrected as nearly all opinion
and thought has been throughout time but has been done so in the spirit of the
original writer with the intent of making his or her thoughts and opinions
clearer and relevant to the reader in the present time.
Fair Use Notice
This site may contain copyrighted material the use of which has
not always been specifically authorized by the copyright owner. We are making
such material available in our efforts to advance understanding of criminal
justice, human rights,
political, economic, democratic, scientific, and social justice issues, etc. We
believe this constitutes a 'fair use' of any such copyrighted material as
provided for in section 107 of the US Copyright Law. In accordance with Title
17 U.S.C. Section 107, the material on this site is distributed without profit
to those who have expressed a prior interest in receiving the included
information for research and educational purposes. For more information see:
www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted
material from this site for purposes of your own that go beyond 'fair use', you
must obtain permission from the copyright owner.
© Lawrence Turner
All Rights Reserved